Skip to main content
Premium Trial:

Request an Annual Quote

Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

NEW YORK (GenomeWeb) – Adaptive Biotechnologies said after the close of the market on Thursday that Medicare contractor Palmetto GBA has established coverage of its next-generation sequencing-based assay, ClonoSeq, for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia.

The US Food and Drug Administration granted de novo premarket authorization to ClonoSeq last year to detect and monitor minimal residual disease by sequencing DNA from bone marrow of patients with some blood cancers.

The coverage is effective immediately. Another Medicare contractor, Noridian, also is covering ClonoSeq, Adaptive said.

"Availability of sensitive, specific, and standardized MRD testing is increasingly crucial to the delivery of optimal patient care in both multiple myeloma and ALL," Nikhil Munshi, director of basic and correlative science at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, said in a statement. "Medicare coverage for the ClonoSeq assay will help ensure that eligible patients across the US have access to a highly advanced option for MRD assessment to support more personalized treatment decisions across their course of care."

Charles Sang, Adaptive's senior vice president of diagnostics, said that the establishment of Medicare coverage "demonstrates the clinical relevance of MRD assessment and underscores the benefit that this test delivers in the management of myeloma and ALL patients."

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.